# Agilent

Source: https://en.bioecon.ru/companies/agilent/
Updated: 2026-06-24

- Country: United States
- Ticker: NYSE:A

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Capacity | $725 million investment to double manufacturing capacity of therapeutic nucleic acids at Frederick, Colorado site | https://www.agilent.com/about/newsroom/presrel/2023/09jan-gp23002.html, https://www.investor.agilent.com/news-and-events/news/news-details/2023/Colorado-Governor-Polis-Helps-Agilent-Break-Ground-on-725-Million-Expansion-of-Manufacturing-Operations-in-Frederick/default.aspx |
| Certification | ISO 13485:2016 (MDSAP) certification for various facilities including locations in the U.S., China, Singapore, and Denmark | https://www.agilent.com/quality/ATI-EN-ISO-13485-2016-MDSAP.pdf, https://www.agilent.com/quality/ISO-13485-MDSAP-TUV.pdf, https://www.agilent.com/quality/hangzhou-ISO13485-EN.pdf |
| Regulatory approval | Products subject to FDA and other global regulatory bodies for approval, including EU In Vitro Diagnostic Regulation compliance | https://www.marketscreener.com/news/agilent-technologies-annual-report-for-fiscal-year-ending-october-31-2025-form-10-k-ce7d50d2dc80f52c, https://www.sec.gov/Archives/edgar/data/1090872/000119312526040293/a-ars-fy25_10-k.pdf |
| Production site | Manufacturing facilities located in California, Colorado, Delaware, Iowa, Massachusetts, Texas, Vermont, Canada, China, Denmark, Germany, Malaysia, and Singapore | https://www.sec.gov/Archives/edgar/data/1090872/000119312526040293/a-ars-fy25_10-k.pdf |
| Headcount | Approximately 18,100 employees as of October 31, 2025 | https://www.marketscreener.com/news/agilent-technologies-annual-report-for-fiscal-year-ending-october-31-2025-form-10-k-ce7d50d2dc80f52c, https://www.sec.gov/Archives/edgar/data/1090872/000119312526040293/a-ars-fy25_10-k.pdf |
| Revenue | $6.948 billion for the fiscal year ended October 31, 2025 | https://www.marketscreener.com/news/agilent-technologies-annual-report-for-fiscal-year-ending-october-31-2025-form-10-k-ce7d50d2dc80f52c, https://www.sec.gov/Archives/edgar/data/1090872/000119312526040293/a-ars-fy25_10-k.pdf |

Independent sources: marketscreener.com, sec.gov

## Technologies

- [Breathomics](https://en.bioecon.ru/technology/breathomics/)
- [Capillary electrophoresis for biopharma](https://en.bioecon.ru/technology/capillary-electrophoresis-biopharma/)
- [Companion diagnostics platforms](https://en.bioecon.ru/technology/companion-diagnostics-platforms/)
- [Gantry robots for wet labs](https://en.bioecon.ru/technology/gantry-robots-for-wet-labs/)
- [HPLC/UPLC instruments for biopharma](https://en.bioecon.ru/technology/hplc-uplc-instruments/)
- [Lab automation & liquid handling](https://en.bioecon.ru/technology/lab-automation-liquid-handling/)
- [Plate readers for bioproduction](https://en.bioecon.ru/technology/plate-readers-bioproduction/)